Egyptian Drug Authority Approves Biomerica's Full Portfolio of Rapid Screening Tests
Reuters
Dec 11
Egyptian Drug Authority Approves Biomerica's Full Portfolio of Rapid Screening Tests
Biomerica Inc. has received authorization from the Egyptian Drug Authority (EDA) for its complete portfolio of rapid screening tests. The approval allows Biomerica to market and distribute its at-home tests for colorectal disease, breast self-exam, prostate disease, kidney disease, and H. pylori infection throughout Egypt. These rapid, easy-to-use, and cost-effective tests are designed for early detection of cancers and chronic diseases, supporting both individual and mass population screenings. The authorization is expected to strengthen preventive healthcare efforts and expand Biomerica's presence in the Middle East and North Africa region. No grants or funding involving other organizations were mentioned.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomerica Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9600581) on December 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.